{"id":7697,"date":"2018-02-06T00:00:00","date_gmt":"2018-02-05T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2018\/02\/06\/el-consorci-europeu-it-liver-amplia-el-coneixement-del-paper-del-tgf-beta-en-cancer-de-fetge\/"},"modified":"2020-05-13T19:46:33","modified_gmt":"2020-05-13T17:46:33","slug":"el-consorci-europeu-it-liver-amplia-el-coneixement-del-paper-del-tgf-beta-en-cancer-de-fetge","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2018\/02\/el-consorci-europeu-it-liver-amplia-el-coneixement-del-paper-del-tgf-beta-en-cancer-de-fetge\/","title":{"rendered":"El consorci europeu IT-LIVER amplia el coneixement del paper del TGF-beta en c\u00e0ncer de fetge"},"content":{"rendered":"

El treball del grup de recerca en TGF-beta i c\u00e0ncer de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) en el context del consorci IT-LIVER (Inhibiting TGF-beta in liver diseases<\/em>), una acci\u00f3 europea col\u00b7laborativa coordinada per la Dra. Isabel Fabregat, ha donat lloc a tres noves publicacions d\u2019impacte que amplien el coneixement sobre els mecanismes moleculars associats a la citoquina TGF-beta en c\u00e0ncer de fetge.<\/p>\n

El consorci IT-LIVER ha proporcionat un programa de formaci\u00f3 en recerca multidisciplinar i interesectorial dirigit a joves investigadors per tal de preparar-los per liderar la recerca en malalties hep\u00e0tiques cr\u00f2niques i el descobriment de f\u00e0rmacs a Europa. En aquest sentit, cal destacar el treball de la investigadora de l\u2019IDIBELL Jitka Soukupova, finan\u00e7ada per aquest projecte, que lidera dos dels tres articles publicats pel grup en els darrers mesos.<\/p>\n

El primer dels articles liderat per la Dra. Soukupova, publicat a\u00a0Scientific Reports<\/em>, analitza el perfil metab\u00f2lic de c\u00e8l\u00b7lules de carcinoma hepatocel\u00b7lular (HCC) que mostren difer\u00e8ncies en els nivells d\u2019expressi\u00f3 de la citoquina TGF-beta; el treball proposa un nou paper protumorig\u00e8nic\u00a0 d\u2019aquesta citoquina en connexi\u00f3 amb la seva capacitat de regular el metabolisme de les c\u00e8l\u00b7lules tumorals i generar un fenotip m\u00e9s invasiu. La recerca ha estat desenvolupada en col\u00b7laboraci\u00f3 amb els grups de Gianluigi Giannelli (IRCCS S. De Bellis, Bari, It\u00e0lia), membre del consorci, Antonio Zorzano (IRB-UB, \u00a0CIBERDEM) i Jos\u00e9 Carlos Perales (IDIBELL-UB).<\/p>\n

L\u2019altre article, publicat per\u00a0Oncotarget<\/em>, explora els mecanismes moleculars darrere l\u2019acci\u00f3 combinada dels f\u00e0rmacs sorafenib i reminostat en el tractament de l\u2019HCC, demostrant com el reminostat contribueix a sensibilitzar les c\u00e8l\u00b7lules a l\u2019acci\u00f3 de sorafenib, ya que contrarresta el fenotip mesenquim\u00e0tic indu\u00eft per la producci\u00f3 de TGF-beta en aquestes c\u00e8l\u00b7lules. En aquest cas, el treball sorgeix fruit de la col\u00b7laboraci\u00f3 amb la empresa 4SC AC (M\u00fanic, Alemanya), en paral\u00b7lel al consorci IT-LIVER.<\/p>\n

D\u2019altra banda, la col\u00b7laboraci\u00f3 amb els grups de Steven Dooley (Universitat de Heidelberg), i Teresa Serrano i Emilio Ramos (IDIBELL-HUB), tamb\u00e9 membres del consorci, ha donat lloc al tercer estudi, liderat per Joaquim Moreno-C\u00e0ceres y Daniel Caballero-D\u00edaz i publicat\u00a0a Cell Death and Disease<\/em>. En aquest cas, s\u2019ha estudiat la relaci\u00f3 entre els nivells de la prote\u00edna de membrana Caveolina-1 (CAV1) i la resposta de TGF-beta, que juga un paper dual en c\u00e0ncer: a l’inici de la patologia, actua com a supressor de tumors, per\u00f2 en estats avan\u00e7ats en pot promoure la progressi\u00f3 tumoral. L\u2019article proposa CAV1 com a biomarcador potencial de cara a estratificar els pacients d\u2019HCC, ja que l\u2019expressi\u00f3 de CAV1 estaria relacionada amb l\u2019acci\u00f3 protumorig\u00e8nica del TGF-beta i l\u2019adequaci\u00f3 d\u2019utilitzar inhibidors d\u2019aquesta via a nivell terap\u00e8utic.<\/p>\n

El consorci IT-Liver, que ha possibilitat la recerca, \u00e9s una xarxa de formaci\u00f3 inicial europea Marie Curie (ITN) liderada des de l’IDIBELL. La cap del grup de recerca en TGF-beta i C\u00e0ncer de l\u2019IDIBELL (programa Oncobell), Isabel Fabregat, \u00e9s la coordinadora del projecte en qu\u00e8 participen vuit institucions acad\u00e8miques d’investigaci\u00f3 i quatre socis industrials procedents de sis pa\u00efsos europeus.<\/p>\n

Durant els \u00faltims 5 anys, IT-Liver ha creat un programa combinat d’investigaci\u00f3 i capacitaci\u00f3 per a investigadors, amb l’objectiu de con\u00e8ixer millor els mecanismes moleculars de la malaltia hep\u00e0tica en qu\u00e8 participa el TGF-beta, a m\u00e9s de proporcionar una comprensi\u00f3 profunda de la biologia molecular de les c\u00e8l\u00b7lules del fetge i millorar tamb\u00e9 les compet\u00e8ncies en activitats de transfer\u00e8ncia de tecnologia (per exemple, gesti\u00f3 de propietat intel\u00b7lectual, valoritzaci\u00f3 i emprenedoria).<\/p>\n

Per saber m\u00e9s sobre IT-LIVER, podeu consultar la web (http:\/\/www.it-liver.eu\/<\/a>) i el\u00a0\u00a0v\u00eddeo<\/a>\u00a0del projecte.<\/p>\n","protected":false},"excerpt":{"rendered":"

El treball del grup de recerca en TGF-beta i c\u00e0ncer de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) en el context del consorci IT-LIVER (Inhibiting TGF-beta in liver diseases), una acci\u00f3 europea col\u00b7laborativa coordinada per la Dra. Isabel Fabregat, ha donat lloc a tres noves publicacions d\u2019impacte que amplien el coneixement sobre els mecanismes moleculars associats […]<\/p>\n","protected":false},"author":6,"featured_media":10611,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,462,360],"tags":[],"class_list":["post-7697","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-nutricio-metabolisme-i-terapia-genica","category-tgf-beta-i-cancer"],"publishpress_future_action":{"enabled":false,"date":"2025-01-03 00:01:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7697"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7697\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10611"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}